ReviewJournal of diabetes and metabolic disorders2026
Pharmacogenomics-Guided therapeutics in type 2 diabetes: Mechanisms, drug Targets, and precision medicine perspectives.
Review in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 Diabetes Mellitus (T2DM) is a global health challenge characterised by pathophysiological diversity, resulting in significant inter-individual variability in drug response. Pharmacogenomics (PGx) offers a powerful approach to personalise T2DM management by linking genetic makeup to therapeutic efficacy and safety. Traditional treatments such as metformin, sulfonylureas, and insulin remain central to management but often present limitations, including adverse effects and declining effectiveness. A comprehensive literature search was conducted across the PubMed, Scopus, and Web of Science databases, covering publications from 2010 to 2025. Search words included "type 2 diabetes," "pharmacogenomics," "drug response," "genetic polymorphism," and "precision medicine". Peer-reviewed studies investigated gene-drug interactions and their underlying mechanisms. Pathways and clinical correlations were critically examined. Emphasis was placed on validated pharmacogenomic markers affecting major antidiabetic drug classes-biguanides,sulfonylureas, thiazolidinediones, incretin-based agents, and SGLT2 inhibitors-while also highlighting emerging genomic associations of exploratory relevance. We outline how genetic diversity influences drug response, moving from pharmacogenetics to broader pharmacogenomic studies that scan the entire genome to identify novel drug targets and deepen the understanding of T2DM pathophysiology. Genomic and electronic health data from large populations have become increasingly available, presenting a transformative opportunity for research and precision medicine within the healthcare system. To effectively utilise genomic information in clinical practice, it is essential to establish a framework for assessing the validity and clinical utility of genomic data and patient electronic health records. This review summarises current evidence, identifies implementation challenges, and discusses future directions to help bridge the gap between pharmacogenomic discoveries and personalised diabetes care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.